# With FDA nod, Regeneron brings an RNAi drug to autoimmune disease

Source: [BioPharma Dive - Latest News](https://www.biopharmadive.com/news/regeneron-fda-approve-cemdisiran-livsayis-myasthenia-gravis-alnylam/875160/) · 2026-11-19 · Medicine
Page: https://themorning.science/story/with-fda-nod-regeneron-brings-an-rnai-drug-to-autoimmune-disease-0355295ee36b6f0f
Kind: launch · Impact: medium

## In brief

- The FDA has approved Livsayis, Regeneron's first marketed RNAi drug, for an autoimmune disease.
- Livsayis is the product of a collaboration between Regeneron and Alnylam.
- It will compete with established autoimmune medicines from AstraZeneca and Argenx.

## Why it matters

It is a new approved drug built on RNA interference, a gene-silencing approach, and it adds a competitor in the autoimmune treatment market.

## Coverage

- [With FDA nod, Regeneron brings an RNAi drug to autoimmune disease](https://www.biopharmadive.com/news/regeneron-fda-approve-cemdisiran-livsayis-myasthenia-gravis-alnylam/875160/) — BioPharma Dive - Latest News, 2026-11-19

Tags: rna interference, drug approval, autoimmune disease, fda, regeneron

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
